title: Molecular pathways in cerebral ischemia: cues to novel therapeutic strategies.
abstract: Stroke is one of the leading causes of death and severe disability in most industrialized countries. Despite the extensive research efforts of both academic and industrial laboratories during the last few decades, no changes have been brought about by the design of neuroprotective therapies. The progressive decrease of stroke-induced death and disability is entirely attributable to improvements in the identification and reduction of risk factors. Over the past few years, experimental research has led to the emergence of a wealth of information regarding the complex and interrelated processes of neuronal degeneration and death triggered by ischemia. This unprecedented insight has led to new theories on the mechanisms of ischemic damage, and has suggested new targets and strategies for therapeutic intervention designed to reduce the clinical consequences of stroke. Among current developments, three strategies seem particularly appealing namely, the limitation of initial or secondary neuronal death by inhibition of apoptotic mechanisms, the enhancement of the endogenous capacity of nervous structures to restore lost function, and the replacement of lost cells by transplantation therapy.
authors.affiliation: INSERM U421, Université Paris XII-Val-de-Marne, Faculté de Médecine, France. ontenien@im3.inserm.fr
authors.forename: Brigitte
authors.initials: B
authors.lastname: Onténiente
authors.forename: Sowmyalakshmí
authors.initials: S
authors.lastname: Rasika
authors.forename: Alexandra
authors.initials: A
authors.lastname: Benchoua
authors.forename: Christelle
authors.initials: C
authors.lastname: Guégan
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects / Q000502:physiology*; D002545:Brain Ischemia / Q000378:metabolism* / Q000503:physiopathology / Q000628:therapy; D016380:Brain Tissue Transplantation; D061945:Caspase Inhibitors; D020169:Caspases / Q000378:metabolism; D006801:Humans; D009336:Necrosis; D009416:Nerve Regeneration / Q000187:drug effects / Q000502:physiology; D018696:Neuroprotective Agents / Q000627:therapeutic use; D020521:Stroke / Q000378:metabolism* / Q000503:physiopathology / Q000628:therapy
chemical_list: D061945:Caspase Inhibitors; D018696:Neuroprotective Agents; D020169:Caspases